• Home
  • Science
    • ImmunoBody®
    • Moditope®
    • Glymab®
    • Publications
  • Pipeline
  • News
  • Investors
    • Share Info
    • Financial Info
    • Documents & Presentations
    • Corporate Governance
  • Contact Us
    • Find a trial
    • Become an Investigator

Clinical & Corporate Update: Active Immunotherapy for a Cancer-Free Future

by chantal | Jun 25, 2025 | Investor Presentations

Annual Report 30th April 2025

by alex | Apr 30, 2025 | Financial Info

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Investor Update: 24 April 2025

by chantal | Apr 25, 2025 | Investor Presentations

Scancell’s new partnership with the NHS Vaccine Launch Pad (CLVP) March 2025

by admin | Apr 14, 2025 | Investor Presentations

H125 reaffirms funds are sufficient to deliver key data

by alex | Jan 30, 2025 | Trinity Delta Reports

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Poised for several pivotal clinical events in 2025

by chantal | Jan 13, 2025 | Trinity Delta Reports

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
« Older Entries
Next Entries »

Recent Posts

  • Result of General Meeting
  • Form F-4 (October 2026)
  • Preliminary Results for the year ended 30 April 2026
  • Atlantic crossing transforms outlook
  • Notice of General Meeting October 2026

Recent Comments

No comments to show.

Scancell is focused on developing novel immunotherapies for the treatment of cancer and was founded in 1996 based on research led by Professor Lindy Durrant at the University of Nottingham in the UK.

  • Follow
  • Follow

Science
Our Pipeline
News
Contact Us
Find a Trial
Become an Investigator

ACTIVE IMMUNOTHERAPY

ImmunoBody®
Moditope®

ANTIBODIES

GlyMab®
AvidiMab®

Investors
Company Profile
Advisors
Corporate Governance
Documents & Presentations
Share Information
Financial Information

Copyright © 2026 Scancell | Website Designed & Developed by Identity Creative | Privacy & Cookie Policy